HOME >> BIOLOGY >> NEWS
Progenika Biopharma presents a biochip that guarantees safety in blood transfusions

agnosis (for diagnoses, prognoses and the prediction of and response to treatment of human diseases). So, in 2004 Progenika launched the LIPOchip on to the market, for the diagnosis of Family Hypercholesterolemia, the first biochip with the CE label and on sale since 2004. Progenika currently has 3 products that are at a development phase and which will finalise at the end of the year.


'"/>

Contact: Irati Kortabitarte
iratik@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
4-Jul-2007


Page: 1 2

Related biology news :

1. Science survey ranks top Biopharma employers
2. FDA grants Accentia Biopharmaceuticals...
3. Accentia Biopharmaceuticals announces option agreement with Mayo
4. AutovaxID-C introduced by Accentia Biopharmaceuticals
5. Accentia Biopharmaceuticals acquires exclusive license
6. Accentia Biopharmaceuticals, Inc. launches CRSFungal Profile
7. SNM presents awards on Capitol Hill
8. ESA presents the sharpest ever satellite map of Earth
9. New book presents neurobiology from an evolutionary perspective
10. Lighting up life: Cold Spring Harbor Protocols presents tips for creating glowing plants
11. Childrens Hospital and Research Center-Oakland presents a new maternal diet study

Post Your Comments:
(Date:5/21/2013)... The American Chemical Society (ACS), the world,s largest ... 246th National Meeting & Exposition, September 8-12, 2013, ... the Indiana Convention Center and at area hotels. ... discoveries that span science,s horizons from astronomy ... broadcast and online journalists a rich assortment of ...
(Date:5/21/2013)... of biomass experts , Where? Copenhagen, ... 03-07 June 2013 , Why? ... assessment, market and policy developments, manufacturing and installation, drawing ... benefiting from its 2013 edition from a record of ... countries, more than 240 plenary and oral presentations, more ...
(Date:5/21/2013)... ANDOVER, Mass. , May 21, 2013 ... that CX50 xMATRIX, the world,s first portable ultrasound with ... Intracardiac Echo (ICE) capability. The CX50 xMATRIX with available ... Paris at the EuroPCR, official ... (EAPCI), May 21-24. Since its launch in ...
Breaking Biology News(10 mins):21st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
(Date:5/21/2013)... 21, 2013  Personal Genome Diagnostics Inc. (PGDx), ... methodologies and expertise in genomic analysis of defined ... collaboration with Blueprint Medicines.  PGDx is an innovator ... alterations in tumors, and Blueprint Medicines is an ... a genetically defined patient population. "This ...
(Date:5/21/2013)... Minneapolis, MN (PRWEB) May 21, 2013 ... a patented automatic colony counter, announced today that they ... four products , the IncuCount, IntelliCount, InCount and ... price and sophistication are especially useful in food microbiology ... been given an updated look. A bright white ...
(Date:5/21/2013)... Mississauga, Ontario (PRWEB) May 21, 2013 ... expert scientists of the ITN to design the ... usefulness of two key clinical models used in ... Chamber (EEC) and Nasal Allergen Challenge (NAC) models. ... supported by numerous publications, to date no direct ...
Breaking Biology Technology:MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
Cached News: